
Ardelyx (ARDX) Stock Forecast & Price Target
Ardelyx (ARDX) Analyst Ratings
Bulls say
Ardelyx is poised for significant revenue growth with the launch of Xphozah and potential FDA approval for Ibsrela in the second half of 2027. The company's innovative platform and promising drug candidates address unmet medical needs and have the potential for high peak sales, making it an attractive investment opportunity. With the support of ArdelyxAssist, the company is well-positioned to successfully market and sell its drugs, further driving revenue and shareholder value.
Bears say
Ardelyx is facing potential challenges with the market expansion of Ibsrela and Xphozah into other conditions such as CIC, as their underlying diseases may be less severe in comparison to those currently treated by the drugs. The expected increase in R&D and SG&A expenses may also have a negative impact on their financials and valuation. In addition, there is a risk of regulatory hurdles and changes in reimbursement pricing that could limit the company's traction in the market.
This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.
Ardelyx (ARDX) Analyst Forecast & Price Prediction
Start investing in Ardelyx (ARDX)
Order type
Buy in
Order amount
Est. shares
0 shares